Clinical trial · Interventional
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05438420CI-TRIAL-00103921active not recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Hepatocellular Cancer | Hepatocellular Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pembrolizumab | Biological | Pembrolizumab | ALIAS |
| Q702 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Dose escalation of Q702 in combination with fixed dose of pembrolizumab
- description
- Give one week on/one week off at selected dose level
- interventionNames
- Drug: Q702
- Biological: Pembrolizumab
- type
- EXPERIMENTAL
- label
- Dose expansion of Q702 in combination with fixed dose of pembrolizumab
- description
- Give intravenously once every three week at 200 mg
- interventionNames
- Drug: Q702
- Biological: Pembrolizumab
Primary outcomes (2)
- measure
- Number of participants with treatment-related adverse events as assessed by CTCAE
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed on treatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies * Have measurable disease per RECIST v 1.1. as assessed by local site investigator/radiology * Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Life expectancy of at least 3 months Exclusion Criteria: * A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women * Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial * Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial * Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis * Has had an allogeneic tissue/solid organ transplant
References
Publications (0)
Data not yet available
No reference posted for this study.